Chen Bihua 4

What Happened
Chen Bihua, listed as a 10% owner of BridgeBio Oncology Therapeutics, Inc. (BBOT), received an award on 2026-06-16 covering 31,675 shares. The Form 4 reports this as a derivative grant (transaction code A) at $0.00 — i.e., an option/award granted rather than an open‑market purchase or sale. No exercise or sale occurred in this filing.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (appears timely).
• Transaction type/code: Award/Grant (A) — derivative instrument covering 31,675 shares.
• Reported price: $0.00 (no cash paid on grant).
• Shares owned after transaction: not specified in the supplied filing summary.
• Footnote (F1): The underlying shares vest in full upon the earlier of (i) the first anniversary of the grant or (ii) the next Annual Meeting of Stockholders, subject to continued service.
• This is a grant of a derivative (option/award), not an immediate sale or exercise.

Context
This filing documents a stock‑based award that will only convert into owned shares if/when vested and any exercise conditions are met; it is not a cash purchase or sale. As a 10% owner, Chen Bihua is a significant holder — the grant may reflect compensation or ownership adjustments rather than routine market trading. The filing appears timely (filed two days after the reported transaction).